Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrochlorothiazide + telmisartan is a fixed-dose combination oral medication used to treat high blood pressure (hypertension). It contains two active ingredients: - **Telmisartan**, an angiotensin II receptor blocker (ARB), which lowers blood pressure by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland. This action prevents vasoconstriction and aldosterone secretion, leading to relaxation of blood vessels and reduced blood pressure. - **Hydrochlorothiazide**, a thiazide diuretic ("water pill"), which reduces plasma volume by increasing renal excretion of sodium and chloride, thereby promoting diuresis. This also helps lower blood pressure. The combination provides greater antihypertensive efficacy than either drug alone, offers effective 24-hour control of blood pressure, and is generally well-tolerated. It is indicated for patients whose hypertension is not adequately controlled with monotherapy[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrochlorothiazide + telmisartan.